Fundraising Fox
/Companies
Sign in

Oncorus Venture Capital

Cambridge, US · Founded 2015 · 8 known investors

Find your way into Oncorus Venture Capital

Sign up to see every warm intro you have to Oncorus Venture Capital

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Oncorus Venture Capital team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Founders & leadership

CQChristophe Queva
Christophe QuevaExecutiveChristophe Queva has held R&D leadership roles at AstraZeneca, Amgen, and Gilead Sciences, where he directed translational science for an approved oncology therapy, and has served as President, CEO, or Chief Scientific Officer at biotech firms including Triptych Therapeutics, Egle Therapeutics, and iTeos. He brings over two decades of experience in oncology and immuno-oncology program development, regulatory strategy, and organizational building, with additional board experience at Bpifrance.
TA
Theodore AshburnNamed on SEC filing
AL
Alon LazarusNamed on SEC filing
CWCameron Wheeler
Cameron WheelerNamed on SEC filingPartner at Deerfield Management Company

Board

BMBriggs Morrison
Briggs MorrisonBoard directorEntrepreneur Partner at MPM BioImpact
MF
Mitchell FinerBoard directorManaging Partner at MPM Capital
LELuke Evnin
Luke EvninBoard directorAdvisor at MPM BioImpact

Investors · 8

IMM Investment Japanlisted by IMM Investment JapanTokyo
Cowen Healthcare InvestmentsreportedNew York

How we know: funding news · press coverage · Not right? Tell us

Deerfield Management CompanyreportedNew York

How we know: funding news · press coverage · Not right? Tell us

IMM InvestmentreportedKangnam

How we know: press coverage · Not right? Tell us

K2 HealthVenturesreportedBoston

How we know: a partner's Signal profile · Not right? Tell us

MPM BioImpactreportedBoston · $1M – $15Mvia Luke Evnin · board

How we know: a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · Not right? Tell us

Sphera Funds ManagementreportedTel Aviv

How we know: press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$115.1M disclosed across 2 rounds · 2016–2019

▶$53.8MraisedDec 2019 · 30 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Theodore AshburnExecutive Officer, Director
  • Briggs MorrisonDirector
  • Mitchell FinerDirector
  • Cameron WheelerDirector
  • Mary Kay FentonDirector
  • Robert KirkmanDirector
  • Spencer NamDirector
  • Christophe QuevaExecutive Officer
  • John McCabeExecutive Officer
  • Luke EvninDirector
Offering amount
$89.6M
Amount sold
$53.8M
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$61.3MraisedSep 2018 · 17 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Briggs MorrisonDirector
  • Theodore AshburnExecutive Officer, Director
  • Mitchell FinerExecutive Officer, Director
  • Alon LazarusDirector
  • Cameron WheelerDirector
  • Luke EvninDirector
  • Christophe QuevaExecutive Officer
Offering amount
$61.4M
Amount sold
$61.3M
First sale
Mar 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Oncorus Venture Capital went on to found or lead other companies.

Luke EvninDirectorFounded MPM BioImpact +1Briggs MorrisonDirectorFounded Crossbow Therapeutics +1Christophe QuevaExecutive OfficerFounded Egle Therapeutics

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

Who are Oncorus Venture Capital's investors?
Oncorus Venture Capital's investors include Astellas Venture Management LLC, IMM Investment Japan, Cowen Healthcare Investments, Deerfield Management Company, IMM Investment, K2 HealthVentures, MPM BioImpact, Sphera Funds Management.
How much funding has Oncorus Venture Capital raised?
Oncorus Venture Capital has disclosed $115.1M raised across 2 rounds.
Where is Oncorus Venture Capital headquartered?
Oncorus Venture Capital is headquartered in Cambridge, US.